Suppr超能文献

在先前自体移植失败的成年患者中,采用减低剂量预处理进行第二次异基因外周血干细胞移植后,移植相关死亡率较低。

Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have failed a prior autologous transplant.

作者信息

Martino R, Caballero M D, de la Serna J, Díez-Martín J L, Urbano-Ispízua A, Tomás J F, Odriozola J, León A, Canals C, San Miguel J, Sierra J

机构信息

Department of Hematology, Hospital de la Santa Creu i Sant Pau, Av Sant Antoni M(a) Claret, 167, 08025 Barcelona, Spain.

出版信息

Bone Marrow Transplant. 2002 Jul;30(2):63-8. doi: 10.1038/sj.bmt.1703606.

Abstract

Standard allogeneic stem cell transplantation (SCT) has been associated with a high transplant-related mortality (TRM) in patients who have failed a prior autologous SCT (ASCT). Reduced-intensity conditioning (RIC) regimens may reduce the toxicities and TRM of traditional myeloablative transplants. We report 46 adults who received a RIC peripheral blood SCT from an HLA-identical sibling in two multicenter prospective studies. The median interval between ASCT and allograft was 16 months, and the patients were allografted due to disease progression (n = 43) and/or secondary myelodysplasia (n = 4). Conditioning regimens consisted of fludarabine plus melphalan (n = 41) or busulphan (n = 5). The 100-day incidence of grade II-IV acute graft-versus-host disease (GVHD) was 42% (24% grade III-IV), and 10/30 evaluable patients developed chronic extensive GVHD. Early complete donor chimerism in bone marrow and peripheral blood was observed in 35/42 (83%) patients, and 16 evaluable patients had complete chimerism 1 year post transplant. With a median follow-up of 358 days (450 in 29 survivors), the 1-year incidence of TRM was 24%, and the 1-year overall (OS) and progression-free survival were 63% and 57%, respectively. Patients who had chemorefractory/ progressive disease, a low performance status or received GVHD prophylaxis with cyclosporine A alone (n = 32) had a 1-year TRM of 35% and an OS of 46%, while patients who had none of these characteristics (n = 32) had a 1-year TRM of 35% and an OS of 46% while patients who had none of these characteristics (n = 14) had a TRM of 0% and an OS of 100%. Our results suggest that adult patients who fail a prior ASCT can be salvaged with a RIC allogeneic PBSCT with a low risk of TRM, although patient selection has a profound influence on early outcome.

摘要

对于既往自体造血干细胞移植(ASCT)失败的患者,标准异基因造血干细胞移植(SCT)与较高的移植相关死亡率(TRM)相关。减低强度预处理(RIC)方案可能会降低传统清髓性移植的毒性和TRM。在两项多中心前瞻性研究中,我们报告了46例接受来自 HLA 相合同胞的RIC外周血SCT的成人患者。ASCT与同种异体移植之间的中位间隔时间为16个月,患者因疾病进展(n = 43)和/或继发性骨髓发育异常(n = 4)而接受同种异体移植。预处理方案包括氟达拉滨加美法仑(n = 41)或白消安(n = 5)。II-IV级急性移植物抗宿主病(GVHD)的100天发生率为42%(III-IV级为24%),30例可评估患者中有10例发生慢性广泛性GVHD。42例患者中有35例(83%)在骨髓和外周血中观察到早期完全供者嵌合,16例可评估患者在移植后1年有完全嵌合。中位随访358天(29例幸存者为450天),1年TRM发生率为24%,1年总生存率(OS)和无进展生存率分别为63%和57%。化疗难治/进展性疾病、低体能状态或仅接受环孢素A预防GVHD的患者(n = 32)1年TRM为35%,OS为46%,而没有这些特征的患者(n = 14)TRM为0%,OS为100%。我们的结果表明,既往ASCT失败的成年患者可以通过RIC异基因外周血干细胞移植挽救,TRM风险较低,尽管患者选择对早期结局有深远影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验